Executive Insights

Volume XVI, Issue 10 | March 28, 2014 | By: Jonathan Kfoury, Ricardo Brau Top 10 biologics by 2013 worldwide sales. Billions of U.S. dollars Key engagement strategies and timing by stakeholder group A range of other payer-engagement models Key strategies to manage the risk from biosimilar competition and win in the biologics market of tomorrow

In this Executive Insights, L.E.K. Consulting argues that the future success of blockbuster branded biologics hinges on the response of three key stakeholder groups  who will play a role in biosimilar adoption—prescribers, patients and payers. Examining these stakeholders in detail, the authors explore a subset of strategies for engagement which underpin an enhanced ability to compete and win in this new and challenging market landscape.

Volume XVI, Issue 9 | March 14, 2014 | By: Ian Tzeng, Ricardo Brau Estimated U.S. annual price for select orphan drugs Overview of orphans’ attractive attributes and challenges Clinical investment criteria for orphan diseases

So-called “orphan diseases” are rare conditions that affect fewer than 200,000 people per year in the U.S. At a time when pharmaceutical firms are contending with an increasingly challenging industry environment, the orphan sector offers the alluring prospect of strong growth and attractive profit margins—along with the opportunity to improve the lives of patients with often debilitating conditions. However, there are several trends that make being a player in orphan drugs a more challenging proposition than in the past.

Volume XVI, Issue 1 | January 21, 2014 | By: Michael Connerty The M&A Learning Curve: Average Total Shareholder Return Above Index (Period 24 months after deal close)

In today's sluggish economic environment, many companies view mergers and acquisitions as a key part of their growth strategies. Buying your way to success is an enticing prospect, but M&A carries unique challenges, and many companies are not immediately prepared to meet those challenges well. Various studies, including one recently published by L.E.K. Consulting, have demonstrated that a majority of mergers destroy shareholder value; creating a whole that is greater than the sum of its parts is easier on paper than in practice.

Volume XV, Issue 17 | August 7, 2013 | By: Michael Connerty

Recently, L.E.K. Consulting analyzed the performance of more than 2,500 M&A deals between 1993 and 2010 and found that nearly 60% destroyed shareholder value. In a new Executive Insights, "Mergers and Acquisitions: What Winners Do to Beat the Odds," L.E.K. Managing Director Michael Connerty identified some of the strategies he sees consistently applied in the minority of deals that end up exceeding shareholder expectations.

Volume XV, Issue 16 | July 15, 2013 | By: Michael Connerty

In this new Executive Insights, L.E.K. shares how management can overcome common pitfalls to beat the long odds of creating value through mergers and acquisitions. From identifying the right target to synergy valuation to post-merger integration, winners have shown that with the right approach, value through M&A can be found and captured.

Volume XV, Issue 12 | May 30, 2013 | By: Alex Evans, Ian Tzeng, Manny Picciola

The U.S. nutraceutical market has experienced rapid growth over the past five years. This fast-growing product segment is already blurring the traditional boundaries between food and pharma. In this new Executive Insights, L.E.K. Consulting proposes that winners in the food versus pharma battle for nutraceutical market share will be those companies that can most quickly and effectively harness the core strengths of both industries; these hybrid products, unsurprisingly, require the best of both worlds.

Volume XV, Issue 6 | April 3, 2013 | By: Ian Tzeng

Despite growing regulation and shrinking budgets, Europe remains a critical market for branded pharmaceutical companies. L.E.K. Consulting offers three strategies to maximize value capture in increasingly access-challenged markets.

Volume XIV, Issue 16 | June 29, 2012 | By: Helen Chen

L.E.K. Consulting believes that there are still advantages to using China as a component of your manufacturing strategy to reach consumers in this growing country, throughout Asia and globally. To that end, we have outlined six important insights to help corporate leaders gain a better understanding of opportunities in China – and in some cases, dispel misperceptions about doing business in this country.

Volume XIV, Issue 12 | May 9, 2012 | By: Alex Vadas, Sue St. Sure, Brian Baranick

L.E.K. Consulting believes that the evolution to more holistic care models will have a broad impact across healthcare stakeholders, creating opportunities for new businesses as well as challenges to the current “one drug/one test” companion diagnostic model. To better understand how the evolution to holistic models is taking shape – and its potential impact on healthcare stakeholders – L.E.K. examined today’s treatment decision support testing landscape and personalized medicine partnership activity. Our findings confirm that more holistic decision support tests and solutions are coming and will require stakeholders to think differently about how they establish themselves by using a broad network of partners and strategic initiatives.

Volume XIV, Issue 11 | May 2, 2012 | By: Clay Heskett

This is the third and final report in the series, “Unlocking Digital Marketing Opportunities for the Pharmaceuticals Sector: Developing a Long-Term Approach to Digital Marketing.” This report looks at maximizing the impact of digital marketing across pharma organizations to realize the full potential of this rapidly evolving approach.